Foreign-Trade Zone (FTZ) 76-Bridgeport, Connecticut; Notification of Proposed Production Activity; MannKind Corporation; (Pharmaceuticals: Treprostinil) Danbury, Connecticut

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

January 13, 2023

Issuing agencies

Commerce DepartmentForeign-Trade Zones Board

Full Text

<html>
<head>
<title>Federal Register, Volume 88 Issue 9 (Friday, January 13, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 9 (Friday, January 13, 2023)]
[Notices]
[Page 2323]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-00564]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-2-2023]


Foreign-Trade Zone (FTZ) 76--Bridgeport, Connecticut; 
Notification of Proposed Production Activity; MannKind Corporation; 
(Pharmaceuticals: Treprostinil) Danbury, Connecticut

    MannKind Corporation submitted a notification of proposed 
production activity to the FTZ Board (the Board) for its facilities in 
Danbury, Connecticut within Subzone 76B. The notification conforming to 
the requirements of the Board's regulations (15 CFR 400.22) was 
received on January 6, 2023.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific finished product(s) described in the submitted 
notification (summarized below) and subsequently authorized by the 
Board. The benefits that may stem from conducting production activity 
under FTZ procedures are explained in the background section of the 
Board's website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed 
finished product(s) would be added to the production authority that the 
Board previously approved for the operation, as reflected on the 
Board's website.
    The proposed finished products are inhalable Treprostinil and 
blister packaged Treprostinil (duty rates are duty-free).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#731507093307011217165d141c05"><span class="__cf_email__" data-cfemail="6107151b2115130005044f060e17">[email&#160;protected]</span></a>. The closing period for their receipt is February 22, 
2023.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Juanita Chen at 
<a href="/cdn-cgi/l/email-protection#fa908f9b94938e9bd499929f94ba8e889b9e9fd49d958c"><span class="__cf_email__" data-cfemail="610b14000f0815004f0209040f2115130005044f060e17">[email&#160;protected]</span></a>.

    Dated: January 9, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023-00564 Filed 1-12-23; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on January 13, 2023.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.